1. Home
  2. LOCO vs STTK Comparison

LOCO vs STTK Comparison

Compare LOCO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

HOLD

Current Price

$10.66

Market Cap

304.0M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$4.07

Market Cap

275.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCO
STTK
Founded
1980
2016
Country
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.0M
275.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LOCO
STTK
Price
$10.66
$4.07
Analyst Decision
Buy
Buy
Analyst Count
4
7
Target Price
$14.50
$6.20
AVG Volume (30 Days)
220.1K
658.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.42
N/A
Revenue Next Year
$1.67
N/A
P/E Ratio
$11.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$0.69
52 Week High
$12.65
$4.89

Technical Indicators

Market Signals
Indicator
LOCO
STTK
Relative Strength Index (RSI) 49.59 53.06
Support Level $10.23 $3.76
Resistance Level $10.98 $4.23
Average True Range (ATR) 0.30 0.32
MACD 0.01 -0.03
Stochastic Oscillator 63.93 56.38

Price Performance

Historical Comparison
LOCO
STTK

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: